Efficacy and safety of RTS,S/AS01 malaria vaccine with or without a booster dose in infants and children in Africa: final results of a phase 3, individually randomised, controlled trial
Top Cited Papers
- 23 April 2015
- journal article
- research article
- Published by Elsevier BV in The Lancet
- Vol. 386 (9988), 31-45
- https://doi.org/10.1016/s0140-6736(15)60721-8
Abstract
No abstract availableKeywords
Funding Information
- GlaxoSmithKline Biologicals SA
- PATH Malaria Vaccine Initiative
- Catalan Government
- Spanish Government
- Medicines for Malaria Venture
- Bill & Melinda Gates Foundation
- Medicines for Malaria Venture
- MVI
- Medicines for Malaria Venture
- GlaxoSmithKline
- Malaria Clinical Trial Alliance
- GlaxoSmithKline
- MVI
- Bill & Melinda Gates Foundation
- MVI
- GlaxoSmithKline Biologicals SA
- GSK Biologicals SA
- PATH MVI
- MVI
- MVI
- Bill & Melinda Gates Foundation
This publication has 13 references indexed in Scilit:
- Efficacy and Safety of the RTS,S/AS01 Malaria Vaccine during 18 Months after Vaccination: A Phase 3 Randomized, Controlled Trial in Children and Young Infants at 11 African SitesPLoS Medicine, 2014
- A Phase 3 Trial of RTS,S/AS01 Malaria Vaccine in African InfantsThe New England Journal of Medicine, 2012
- Validation of an enzyme-linked immunosorbent assay for the quantification of human IgG directed against the repeat region of the circumsporozoite protein of the parasite Plasmodium falciparumMalaria Journal, 2012
- First Results of Phase 3 Trial of RTS,S/AS01 Malaria Vaccine in African ChildrenThe New England Journal of Medicine, 2011
- Relation between falciparum malaria and bacteraemia in Kenyan children: a population-based, case-control study and a longitudinal studyThe Lancet, 2011
- From the circumsporozoite protein to the RTS,S/AS candidate vaccineHuman Vaccines, 2010
- Randomized Controlled Trial of RTS,S/AS02D and RTS,S/AS01E Malaria Candidate Vaccines Given According to Different Schedules in Ghanaian ChildrenPLOS ONE, 2009
- Randomized, Double‐Blind, Phase 2a Trial of Falciparum Malaria Vaccines RTS,S/AS01B and RTS,S/AS02A in Malaria‐Naive Adults: Safety, Efficacy, and Immunologic Associates of ProtectionThe Journal of Infectious Diseases, 2009
- Five-year safety and immunogenicity of GlaxoSmithKline’s candidate malaria vaccine RTS,S/AS02 following administration to semi-immune adult men living in a malaria-endemic region of The GambiaHuman Vaccines, 2009
- Clinical features and prognostic indicators in paediatric cerebral malaria: a study of 131 comatose Malawian children.1989